We are extremely pleased and enthusiastic that we can count upon the valued support of Business Angels Marne-Ardennes (BAMA, former Reims Business Angels)!
This enables Apmonia Therapeutics to accelerate the development of its lead candidate AP-01 in solid tumors, while strengthening R&D team and increasing the company’s attractiveness towards industrial partners and investors.
As part of the “Cancer Biology and Basic Sciences” 2020 call for proposals, our ambitious project aims at opening new therapeutic perspectives for the treatment of ovarian cancer, one of the highest unmet medical needs in oncology.
Press release: SATT Nord and Apmonia Therapeutics have entered into agreements in which Apmonia Therapeutics has been granted an exclusive worldwide license for the development and commercialization of the innovative anti-cancer immunotherapy (TAX2 peptide).
CREA, 2 Esplanade Roland Garros, 51686 Reims Cedex 2, France
En poursuivant votre navigation, vous acceptez l’utilisation des cookies permettant de réaliser des études d’audience et de vous proposer du contenu, des services, et des offres adaptées à vos centres d’intérêts. Pour en savoir plus, consultez notre politique de Protection des Données Personnelles. J'accepte
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.